Jan Leslie Hillson

US Patent:

20220218785, Jul 14, 2022

Filed:

Apr 16, 2020

Appl. No.:

17/603827

Inventors:

- Seattle WA, US
Jing YANG - Seattle WA, US
Stanford PENG - Seattle WA, US
Jan HILLSON - Seattle WA, US

Assignee:

Alpine Immune Sciences, Inc. - Seattle WA

International Classification:

A61K 38/13
A61K 38/17
A61P 29/00
A61P 31/12
A61P 37/06

Abstract:

Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

US Patent:

20210238275, Aug 5, 2021

Filed:

Jul 31, 2017

Appl. No.:

16/321801

Inventors:

Sucharita Roy - Acton MA, US
Nathaniel Washburn - Cambridge MA, US
Marilyn Kehry - San Diego CA, US
David J. King - Encinitas CA, US
Anthony Manning - Cambridge MA, US
James Meador, III - Framingham MA, US
Jan Hillson - Cambridge MA, US

International Classification:

C07K 16/28
A61P 37/02

Abstract:

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.